Clinical Trial

Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Dry Powder Inhalation of Treprostinil

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated January 29, 2025 (before its estimated May 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
The primary objective of this study is to evaluate the long-term safety of LIQ861 in patients with pulmonary arterial hypertension (PAH).
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2019-06-18; most recent amendment 2025-01-28.
Status change: Enrolling by Invitation → Active, Not Recruiting 2020-04-14
Status change: Not Yet Recruiting → Enrolling by Invitation 2019-09-11
Trial Details
NCT Number NCT03992755
Lead Sponsor Liquidia Technologies, Inc.
Collaborators: Nuventra, Inc.
Conditions Primary Pulmonary Hypertension
Enrollment 92 participants
Start Date 2019-07-18
Primary Completion 2025-05-31 (estimated)
Study Completion 2025-05-31 (estimated)
Updated on ClinicalTrials.gov 2025-01-29